PubMed Health⌕ Search

Biomedical subjects

M Pétrover

Publications and source records attributed to M Pétrover.

11 recordsLinked to original sources
PubMed1999

Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors.

Cardiovascular diseases represent the major cause of death in hemodialysis patients. However, little information is available about the repercussion of uremia on cardiac valves. We retrospectively investigated the incidence rate of aortic stenosis (AS), from 1991 to 1996, in 110 hemodialysis patients followed by Doppler-echocardiography. Progressive AS was diagnosed in 16 patients who had a decrease in their indexed aortic valve area from 1.24 +/- 0.09 to 0.66 +/- 0.21 cm2/m2 of BSA in 16.8 +/- 1.9 months. The mean incidence of AS per year was of 3.3%, ranging from 1.5 to 8.0%. Eight patients died in less than 3 years after the diagnosis of AS with a mean survival time of 23.0 +/- 9.5 months. Survival curves using Kaplan-Meier estimates showed a statistically significant decrease in the survival rate of patients with AS compared with patients without valvulopathy (p < 0.001). They were older than patients with normal valve, 68.6 +/- 11.1 versus 56.7 +/- 16.0 years, respectively. Men were 4 times more affected than women and showed a significantly more rapid progression to AS than women. The calcium-phosphorus product was higher in AS patients, 5.43 +/- 0.98 than in patients without AS, 3.95 +/- 0.50 mM. It was mainly due to hyperphosphatemia without hypercalcemia and the hyperphosphatemia was associated with biological signs of hypoparathyroidism or adynamic bone disease in 62% of the cases. Plasma vitamin D3 was also higher in patients with AS, 20.5 +/- 13.5 ng/ml than in those with normal valves, 9.6 +/- 6.3 ng/ml. Logistic regression showed that age, vitamin D3 and hyperphosphatemia correctly predicted 56% of the AS cases. In conclusion, AS is frequent and of poor outcome in hemodialysis patients. Age, relatively high plasma vitamin D3 levels, and hyperphosphatemia, mostly due to hypoparathyroidism, must be considered as risk factors.

Adult↗
PubMed1998

Secondary hyperparathyroidism: detection with I-123-Tc-99m-Sestamibi subtraction scintigraphy versus US.

PURPOSE: To compare iodine-123-technetium-99m-sestamibi subtraction scintigraphy with ultrasonography (US) for detection of parathyroid abnormalities in uremic patients with secondary hyperparathyroidism. MATERIALS AND METHODS: Fourteen adult uremic patients with severe secondary hyperparathyroidism underwent subtraction scintigraphy before total or subtotal parathyroidectomy. Subtraction scintigrams were acquired with a double-energy-window technique. US was performed with high-frequency transducers and standard methods. RESULTS: 1-123-Tc-99m-sestamibi subtraction scintigraphy correctly demonstrated 41 of 50 surgically confirmed enlarged parathyroids; US demonstrated 27. Sensitivity for detection of hyperplastic glands was 82% for scintigraphy and 54% for US. Scintigrams were correct in seven patients, and US scans were correct in five. Scintigraphy demonstrated all four enlarged parathyroids in six of 12 patients who were to undergo first surgery, whereas US demonstrated all four enlarged glands in three of the 12 patients. Gland weight was correlated with likelihood of detection with either method. Glands undetected at scintigraphy were significantly (P < .01) smaller (mean weight, 257 mg) than those undetected at US (mean weight, 467 mg). CONCLUSION: I-123-Tc-99m-sestamibi subtraction scintigraphy is efficient for detection of enlarged parathyroid glands in uremic patients with secondary hyperparathyroidism and is more sensitive than US.

Adult↗
PubMed1997

[Incidence and development of aortic stenosis in chronic hemodialysis. An ultrasonographic and biological study of 112 patients].

Valvular calcification in chronic haemodialysis patients has already been reported in the literature, particularly the abnormally high incidence of aortic stenosis. In this study, 112 haemodialysis patients were followed up by Doppler echocardiography for a period of 36 months. Sixteen patients developed aortic valvular calcification with aortic stenosis over an 18.7 +/- 7.5 months period. The indexed aortic valve surface area decreased from 1.24 +/- 0.9 cm2/m2 to 0.66 +/- 0.21 cm2/m2 with abnormally rapid progression. Eight patients with aortic stenosis died during the 3 year study period. These results reflect the abnormal extra-skeletal calcification of chronic haemodialysis patients. Several predisposing factors were demonstrated: age (68.5 +/- 11.1 years versus 57.1 +/- 16.3 years in patients without calcifications), male gender, a longer period of dialysis than the patients without aortic stenosis (8.1 +/- 5.3 versus 5.9 +/- 5.7 years), abnormalities of calcium and phosphate metabolism, increased of the phosphocalcic product by hyperphosphoraemia and not by hypercalcaemia, hypoparathyroidism in 62% and hyperparathyroidism in 38% an increase in vitamin D 3 (19.7 +/- 14 ng/ml versus 9.6 +/- 6.3 ng/ml) biological signs of adynamic osteodystrophy. Calcific aortic stenosis is a commonly observed valvular lesion in haemodialysis patients: its progression may be very rapid, associated with a poor prognosis. Old age, male gender, duration of haemodialysis, hyperphosphataemia associated with hypoparathyroidism and raised Vitamin D3 are predisposing factors.

Aged↗
PubMed1996

[Alkaline phosphatase of bone origin in hemodialyzed patients. 110 assays].

OBJECTIVES: To evaluate the value of plasma bone-specific alkaline phosphatase (bAP) in the diagnosis and the prediction of the type of renal osteodystrophy in hemodialysis patients. To examine whether bAP correlated with the two classical biochemical markers of bone turnover in dialysis patients which are total alkaline phosphatases (tAP) and intact PTH (iPTH). METHODS: One hundred adult uremic patients undergoing regular hemodialysis therapy were included in the study. Plasma bAP was determined using a radioimmunometric assay. Intact PTH (1-84) was measured using a radioimmunometric assay, Allegro Intact PTH, Nichols Institute, CA, USA. Other laboratory tests including calcium, phosphorus, and tAP were performed by automated methods. RESULTS: Based on previous biochemical and histological data obtained in the same type of patients, we arbitrarily divided plasma bAP levels in normal (10-20 ng/ml), low (< 10 ng/ml), and high (> 20 ng/ml). We found here that bAP levels were normal in 27 patients, high in 36, and low in 37. In the group with normal bAP, 8/27 patients had iPTH levels higher than 200 pg/ml, the other 19 patients had an iPTH within the normal range. In the 36 patients with high bAP, 10 showed markedly high iPTH and clinical signs of severe hyperparathyroidism leading to the indication of a surgical parathyroidectomy in 7 patients and i.v. calcitriol therapy in the other 3. However, 9 of these 36 patients had an iPTH lower than 200 pg/ml and 17 between 200-500 pg/ml. In the 37 patients with low bAP, iPTH levels were also low in 15 of them, but 12 patients had iPTH levels higher than 200 pg/ml. There was a good correlation between bAP, tAP, and iPTH. However, bAP correlated better with iPTH than tAP. A bAP > 20 ng/ml had a sensitivity of 56%, specificity of 92% and positive predictive value of 80% in the prediction of an PTH higher than > 400 pg/ml and therefore of the biological diagnosis of hyperparathyroidism. A bAP < 10 ng/ml had a sensitivity of 70%, specificity of 56% and a positive predictive value of 48% in predicting a normal-low iPTH (< 100 pg/ml). CONCLUSION: In the absence of bone biopsy, plasma bAP self provides useful information about bone remodeling in hemodialysis patients. The combination of bAP and iPTH measurements further define the type of bone turnover. either elevated plasma bAP or iPTH alone are no always anonymous with secondary hyperparathyroidism.

Adult↗